TVARDI THERAPEUTICS, INC. Research and Development Expense
TVARDI THERAPEUTICS, INC. (TVRD) reported Research and Development Expense of $4.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $4.00M, a 31.07% decline year-over-year.
- TVARDI THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $4.91M, a 57.86% increase year-over-year.
- TVARDI THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $5.49M, a 36.17% decline year-over-year.
- TVARDI THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $3.60M, a 24.86% decline year-over-year.
- TVARDI THERAPEUTICS, INC. research and development expense for fiscal 2025 was $18.01M, a 23.84% decline from fiscal 2024.
- TVARDI THERAPEUTICS, INC. research and development expense for fiscal 2024 was $23.65M, a 78.20% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. research and development expense for fiscal 2023 was $108.51M, a 18.10% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. research and development expense for fiscal 2022 was $91.88M, a 11.10% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.00M 10-Q · filed 2026-08-14 | $8.91M 10-Q · filed 2026-08-14 | $14.40M derived: sum of 3 quarters · filed 2026-08-14 | $18.01M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $4.91M 10-Q · filed 2026-05-08 | $10.40M derived: sum of 2 quarters · filed 2026-05-08 | $14.01M derived: sum of 3 quarters · filed 2026-05-08 | $19.81M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.09M derived: sum of 2 quarters · filed 2026-03-31 | $14.90M derived: sum of 3 quarters · filed 2026-08-14 | $18.01M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $3.60M 10-Q · filed 2025-11-13 | $9.41M derived: sum of 2 quarters · filed 2026-08-14 | $12.52M 10-Q · filed 2025-11-13 | $21.12M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $5.81M 10-Q · filed 2026-08-14 | $8.92M 10-Q · filed 2026-08-14 | $17.52M derived: sum of 3 quarters · filed 2026-08-14 | $22.32M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $3.11M 10-Q · filed 2026-05-08 | $319.00K 10-Q · filed 2025-05-13 | $11.71M derived: sum of 2 quarters · filed 2026-05-08 | $16.51M derived: sum of 3 quarters · filed 2026-05-08 | $23.04M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $13.40M derived: sum of 2 quarters · filed 2026-03-31 | $19.93M derived: sum of 3 quarters · filed 2026-03-31 | $23.65M 10-K · filed 2026-03-31 | $32.80M 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $4.79M 10-Q · filed 2025-11-13 | $1.36M 10-Q · filed 2024-11-14 | $11.33M derived: sum of 2 quarters · filed 2025-11-13 | $15.05M 10-Q · filed 2025-11-13 | $32.63M 10-Q · filed 2024-11-14 | $61.70M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $6.53M 10-Q · filed 2025-08-14 | $9.31M 10-Q · filed 2024-08-14 | $10.25M 10-Q · filed 2025-08-14 | $31.27M 10-Q · filed 2024-08-14 | $56.91M derived: sum of 3 quarters · filed 2025-08-14 | $82.36M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $21.96M 10-Q · filed 2025-05-13 | $50.38M derived: sum of 2 quarters · filed 2025-05-13 | $75.83M derived: sum of 3 quarters · filed 2025-05-13 | $106.14M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $28.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $53.87M derived: sum of 2 quarters · filed 2025-03-11 | $84.18M derived: sum of 3 quarters · filed 2025-03-11 | $108.51M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $25.45M 10-Q · filed 2024-11-14 | $55.76M derived: sum of 2 quarters · filed 2024-11-14 | $80.09M 10-Q · filed 2024-11-14 | $106.11M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-06-30 | $30.31M 10-Q · filed 2024-08-14 | $54.64M 10-Q · filed 2024-08-14 | $80.65M derived: sum of 3 quarters · filed 2025-03-11 | $105.34M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-03-31 | $24.33M 10-Q · filed 2024-05-13 | $50.34M derived: sum of 2 quarters · filed 2025-03-11 | $75.03M derived: sum of 3 quarters · filed 2025-03-11 | $94.94M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2022-12-31 | $26.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $50.70M derived: sum of 2 quarters · filed 2025-03-11 | $70.61M derived: sum of 3 quarters · filed 2025-03-11 | $91.88M 10-K · filed 2025-03-11 | ||||
| 2022-09-30 | $24.69M 10-Q · filed 2023-11-13 | $44.60M derived: sum of 2 quarters · filed 2023-11-13 | $65.87M 10-Q · filed 2023-11-13 | $88.70M derived: sum of 4 quarters · filed 2024-03-06 | ||||
| 2022-06-30 | $19.91M 10-Q · filed 2023-08-07 | $41.18M 10-Q · filed 2023-08-07 | $64.01M derived: sum of 3 quarters · filed 2024-03-06 | $79.52M derived: sum of 4 quarters · filed 2024-03-06 | ||||
| 2022-03-31 | $21.27M 10-Q · filed 2023-05-15 | $44.10M derived: sum of 2 quarters · filed 2024-03-06 | $59.62M derived: sum of 3 quarters · filed 2024-03-06 | $84.84M derived: sum of 4 quarters · filed 2024-03-06 | ||||
| 2021-12-31 | $22.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $38.34M derived: sum of 2 quarters · filed 2024-03-06 | $63.57M derived: sum of 3 quarters · filed 2024-03-06 | $82.70M 10-K · filed 2024-03-06 | ||||
| 2021-09-30 | $15.51M 10-Q · filed 2022-11-07 | $40.74M derived: sum of 2 quarters · filed 2022-11-07 | $59.87M 10-Q · filed 2022-11-07 | $87.01M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-06-30 | $25.23M 10-Q · filed 2022-08-08 | $44.36M 10-Q · filed 2022-08-08 | $71.50M derived: sum of 3 quarters · filed 2023-03-06 | $92.56M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-03-31 | $19.13M 10-Q · filed 2022-05-09 | $46.27M derived: sum of 2 quarters · filed 2023-03-06 | $67.34M derived: sum of 3 quarters · filed 2023-03-06 | $93.45M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2020-12-31 | $27.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $48.21M derived: sum of 2 quarters · filed 2023-03-06 | $74.31M derived: sum of 3 quarters · filed 2023-03-06 | $107.85M 10-K · filed 2023-03-06 | ||||
| 2020-09-30 | $21.07M 10-Q · filed 2021-11-08 | $47.17M derived: sum of 2 quarters · filed 2021-11-08 | $80.71M 10-Q · filed 2021-11-08 | $110.58M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $26.11M 10-Q · filed 2021-08-09 | $59.64M 10-Q · filed 2021-08-09 | $89.51M derived: sum of 3 quarters · filed 2022-03-01 | $125.50M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $33.54M 10-Q · filed 2021-05-10 | $63.40M derived: sum of 2 quarters · filed 2022-03-01 | $99.39M derived: sum of 3 quarters · filed 2022-03-01 | $123.75M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $29.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $65.86M derived: sum of 2 quarters · filed 2022-03-01 | $90.21M derived: sum of 3 quarters · filed 2022-03-01 | $113.82M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $35.99M 10-Q · filed 2020-11-09 | $60.35M derived: sum of 2 quarters · filed 2020-11-09 | $83.96M 10-Q · filed 2020-11-09 | $106.75M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $24.36M 10-Q · filed 2020-08-10 | $47.96M 10-Q · filed 2020-08-10 | $70.76M derived: sum of 3 quarters · filed 2021-02-25 | $93.07M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $23.61M 10-Q · filed 2020-05-11 | $46.41M derived: sum of 2 quarters · filed 2021-02-25 | $68.71M derived: sum of 3 quarters · filed 2021-02-25 | $85.71M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $22.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $45.10M derived: sum of 2 quarters · filed 2021-02-25 | $62.10M derived: sum of 3 quarters · filed 2021-02-25 | $75.53M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $22.30M 10-Q · filed 2019-11-05 | $39.30M derived: sum of 2 quarters · filed 2019-11-05 | $52.73M 10-Q · filed 2019-11-05 | $64.31M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $17.00M 10-Q · filed 2019-08-07 | $30.43M 10-Q · filed 2019-08-07 | $42.01M derived: sum of 3 quarters · filed 2020-02-27 | $51.16M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $13.43M 10-Q · filed 2019-05-07 | $25.00M derived: sum of 2 quarters · filed 2020-02-27 | $34.15M derived: sum of 3 quarters · filed 2020-02-27 | $41.12M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $11.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $20.73M derived: sum of 2 quarters · filed 2020-02-27 | $27.69M derived: sum of 3 quarters · filed 2020-02-27 | $48.52M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $9.15M 10-Q · filed 2018-11-06 | $16.11M derived: sum of 2 quarters · filed 2018-11-06 | $36.95M 10-Q · filed 2018-11-06 | $57.23M derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2017-06-30 | $6.96M 10-Q · filed 2018-08-07 | $27.80M 10-Q · filed 2018-08-07 | $48.07M derived: sum of 3 quarters · filed 2019-03-12 | $57.74M derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2017-03-31 | $20.84M 10-Q · filed 2018-05-09 | $41.11M derived: sum of 2 quarters · filed 2019-03-12 | $50.78M derived: sum of 3 quarters · filed 2019-03-12 | $61.54M derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2016-12-31 | $20.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $29.95M derived: sum of 2 quarters · filed 2019-03-12 | $40.71M derived: sum of 3 quarters · filed 2019-03-12 | $49.25M 10-K · filed 2019-03-12 | ||||
| 2016-09-30 | $9.67M 10-Q · filed 2017-11-02 | $20.43M derived: sum of 2 quarters · filed 2017-11-02 | $28.98M 10-Q · filed 2017-11-02 | $36.55M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-06-30 | $10.76M 10-Q · filed 2017-08-03 | $19.30M 10-Q · filed 2017-08-03 | $26.87M derived: sum of 3 quarters · filed 2018-03-15 | $32.46M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-03-31 | $8.55M 10-Q · filed 2017-05-04 | $16.11M derived: sum of 2 quarters · filed 2018-03-15 | $21.70M derived: sum of 3 quarters · filed 2018-03-15 | $26.38M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-12-31 | $7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $13.15M derived: sum of 2 quarters · filed 2018-03-15 | $17.84M derived: sum of 3 quarters · filed 2018-03-15 | $21.22M 10-K · filed 2018-03-15 | ||||
| 2015-09-30 | $5.58M 10-Q · filed 2016-11-04 | $10.27M derived: sum of 2 quarters · filed 2016-11-04 | $13.65M 10-Q · filed 2016-11-04 | $17.11M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2015-06-30 | $4.68M 10-Q · filed 2016-08-04 | $8.07M 10-Q · filed 2016-08-04 | $11.53M derived: sum of 3 quarters · filed 2017-03-10 | $17.74M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2015-03-31 | $3.38M 10-Q · filed 2016-05-05 | $6.84M derived: sum of 2 quarters · filed 2017-03-10 | $13.05M derived: sum of 3 quarters · filed 2017-03-10 | $16.25M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2014-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $9.67M derived: sum of 2 quarters · filed 2017-03-10 | $12.87M derived: sum of 3 quarters · filed 2017-03-10 | $15.07M 10-K · filed 2017-03-10 | ||||
| 2014-09-30 | $6.21M 10-Q · filed 2015-11-09 | $9.41M derived: sum of 2 quarters · filed 2015-11-09 | $11.61M 10-Q · filed 2015-11-09 | $13.59M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2014-06-30 | $3.20M 10-Q · filed 2015-08-10 | $5.40M 10-Q · filed 2015-08-10 | $7.38M derived: sum of 3 quarters · filed 2016-03-11 | $11.14M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2014-03-31 | $2.20M 10-Q · filed 2015-05-12 | $4.18M derived: sum of 2 quarters · filed 2016-03-11 | $7.94M derived: sum of 3 quarters · filed 2016-03-11 | $9.96M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2013-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $5.74M derived: sum of 2 quarters · filed 2016-03-11 | $7.76M derived: sum of 3 quarters · filed 2016-03-11 | $8.69M 10-K · filed 2016-03-11 | ||||
| 2013-09-30 | $3.76M 10-Q · filed 2014-11-10 | $5.79M derived: sum of 2 quarters · filed 2014-11-10 | $6.71M 10-Q · filed 2014-11-10 | |||||
| 2013-06-30 | $2.02M 10-Q · filed 2014-08-07 | $2.94M 10-Q · filed 2014-08-07 | ||||||
| 2013-03-31 | $922.00K 10-Q · filed 2014-05-12 | |||||||
| 2012-12-31 | $4.60M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |